Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

Glioblastoma and all gliomas – Tafinlar plus Mekinist, a durable benefit

Background – Glioblastoma and BRAF

BRAFV600E mutations are rarely encountered in adult glioblastoma with an incidence ranging from less than 1% to 8%. But young adults, i.e. 17 to 35 years, seem to have higher mutation rates of up to 15%.

BRAF V600E mutations should be considered for routine testing as they are part of the many factors that drive the development of many cancers.

Tafinlar is a drug which targets BRAFV600E mutations and therefore can cause the tumor to stop growing and kill its cells.

Mekinist is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2 which are components in the inner part of the tumor cell that also contribute to its growth and proliferation.

The combination of these two drugs is approved for treating Melanoma patients.

And now a durable clinical benefit was seen from this combination in treating patients with BRAF V600E mutant low- and high-grade glioma, such as Glioblastoma. It was a phase 2 study by the name ” ROAR study”.

About the ROAR clinical trial

ROAR was a study of Tafinlar and Mekinist in patients with BRAF V600E mutation–positive rare cancers.

37 patients with glioma were enrolled and included in the primary analysis.

Only patients with advanced disease and no available standard treatment options were eligible for enrollment to the study.

Patients received Tafinlar 150 mg twice daily and Mekinist 2 mg once daily.

Results of the High Grade Glioma Cohort, e.g. Glioblastoma

  • 24% of patients had their tumor decrease in volume
  • 7% of patients had their tumors vanished from the MRI!
  • The median duration of response was 36.9 months (over 3 years)
  • At 2 years, 68.8% of patients were still responding to the treatment
  • The median survival was 17.6 months which is more than the standard of care. Mind this is “median” – meaning 50% lived longer than 17.6 months and 50% less.

Results of the Law Grade Glioma Cohort

  • 69.0% of patients had their tumor decrease in volume
  • 8% of patients had their tumors vanished from the MRI!
  • The median duration of response was not reached
  • At 2 years, 76.2% of patients were still responding to the treatment
  • The median survival was still not reached at the time of the analysis

Side Effects

The hardest side effects were fatigue (9% of patients), neutrophil count decreased (9%), headache (5%) and neutropenia (5%).

Some patients needed dose reduction and some stopped the treatment due to the side effects.

Contact us so we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

For further reading>>

More information about Glioblastoma>>

Gliomas - Mekinist plus Tafinlar
Gliomas – Mekinist plus Tafinlar

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics